Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-0869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-target combination treatment with rTMS and tDCS for Tourette syndrome: a case report.
Front Hum Neurosci
January 2025
The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Tourette syndrome (TS) is a neuropsychiatric disorder characterized by chronic motor and phonic tics, with a higher prevalence among boys. This condition can significantly impact patients' learning and daily life. Due to the limited efficacy and potential side effects of pharmacological treatments for TS, there is a critical need to develop novel, tailored therapeutic strategies.
View Article and Find Full Text PDFImprovement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
Cureus
December 2024
Department of Dermatology, Duke University Medical Center, Durham, USA.
Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management.
View Article and Find Full Text PDFUtility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol Glob
February 2025
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.
Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.
Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.
Biologic Treatments for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): A Comparative Review of Efficiency and Risks.
Cureus
January 2025
Department of Otolaryngology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, ROU.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the nasal passages and sinuses, often characterized by nasal congestion, loss of smell, facial pressure, and nasal discharge. Conventional treatments, such as corticosteroids and endoscopic sinus surgery (ESS), often provide only temporary relief, with frequent recurrence of symptoms. For patients with severe, refractory CRSwNP, biologic therapies have emerged as a promising treatment option.
View Article and Find Full Text PDFIleal pouch-anal anastomosis for ulcerative colitis: 30-year analysis on surgical evolution and patient outcome.
BJS Open
December 2024
Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Background: Proctocolectomy with ileal pouch-anal anastomosis is the treatment of choice for patients with ulcerative colitis with medical refractory disease or dysplasia. The aim of this research was to describe the evolution of ileal pouch-anal anastomosis surgery and surgical outcomes over a three-decade interval in a high-volume referral centre.
Methods: All consecutive patients undergoing ileal pouch-anal anastomosis for ulcerative colitis between 1990 and 2022 at the University Hospitals of Leuven were retrospectively included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!